4 May 2022

Simmunext: where immunotherapy and chemistry meet

The story behind Oncode’s newest spinoff, Simmunext Biotherapeutics B.V.

Bianca-Olivia Nita

Bianca-Olivia Nita

Simmunext is a company name made of three words - a mix of ‘simulation’ (referring to simulating the immune system), ‘immune’ (referencing the immune system) and ‘next’ (indicating a next-generation approach). This describes the innovative approach Oncode Investigator Carl Figdor has developed to create polymers which can act as artificial antigen-presenting cells to stimulate the immune system to obtain a therapeutic response. With a strong IP position and management team in place, the company is now ready for its journey to leverage this platform technology to bring novel cancer therapies to the clinic.

Decades ago, the scientific community was sceptical. Many thought that cancer was all about genetics and had nothing to do with immunology. But things have changed. Today it is widely known the immune system can contribute to fighting cancer, with successes seen for example in treating lung cancer and melanoma.

There are three types of immunotherapies used nowadays. Antibodies, vaccines and cell therapies, the latter using an effective method of taking cells from the patient, engineering them, then giving them back to the patient so they can fight the cancer they are engineered against.

The lab of Oncode Investigator Carl Figdor has been working with dendritic cells for a long time. These are immune cells that present antigens to T-cells, which then target cancer cells expressing the antigen they are activated against. “I always found that because you are getting these cells from patients, the procedure can be very difficult. Sometimes the patient is not in such a good condition, or they are immunosuppressed. Or we simply don’t get enough cells. The protocol was always variable, because the material we could get from the patients was variable” explains Figdor.

But after connecting with the chemistry department at Radboud University, he got interested in the polymers this department made. “I asked myself - could I try to mimic the immune system? Could I make artificial antigen-presenting cells by using polymers?” Figdor recalls. “Of course, these are not cells, these are polymers. But I could equip them with molecules that can also be found on immune cells”.

Soon enough he received his an ERC advanced grant to develop this idea further and two years ago, received a second one to continue this work, helping him demonstrate what is now clear: that using chemistry to mimic live cells can work. “This also helped me develop the technology – the immunofilaments - that can efficiently make immune cells more fit and more robust for immunotherapy.”

The creation of Simmunext – for which Henri Theunissen will serve as CEO - means bringing a decade of work to the next level and taking steps towards the clinic. “Without Oncode’s support, I wouldn’t so easily have taken this path. As an academic, starting a company never received priority. But the Oncode valorization team – Ian Bell and Shobit Dhawan in particular – stimulated me and convinced me this is the logical next step” explains Figdor.

“We want to develop a therapeutic drug and doing so is extremely expensive, not something an academic hospital can easily afford. We also secured several patents. We are in good shape and now the real work starts” he says with a laugh. “We must make a big step to translate this to the clinic and the next two years are crucial in getting there” he concludes.

Other News

Vidi 12
Vidi Grants awarded to Miao-Ping Chien, Rebekka Schneider, Tineke Lenstra and Monique Mulder
Oncode Institute is proud to announce that three Oncode Investigators and one Oncode Researcher will receive a Vidi Grant worth 800.000 euros. This grant will enable Oncode Investigators Miao-Ping Chien, Rebekka Schneider (both Erasmus MC), Tineke Lenstra (Netherlands Cancer Institute) and Oncode Researcher Monique Mulder (Leiden UMC) to develop their own innovative line of research and set up their own research group in the coming five years.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Banner Wilbert Zwart Lymphnode Universe CMYK
Prostate cancer hijacks tumor cell biorhythm to evade hormone therapy
Hormone therapy is successful at keeping metastatic prostate cancer under control, but eventually the tumor cells become resistant to it. An unexpected potential solution has now emerged in medicines not designed to fight cancer, but to target proteins that regulate a cell’s circadian rhythm. Oncode Investigator Wilbert Zwart and others publish about this discovery in cancer discovery today.
ElizeBrolsma

<span>Elize</span><span>Brolsma</span>

Elize is part of Oncode’s communication team. She has over 10 years of experience in the com-munication industry, both for commercial and non-profit organisations. After obtaining her bache-lor and master degree in communication at Utrecht University, Elize worked as a communication professional at a research institute, PR agency, law firm and internet company. She has a strong focus on external communications and Public Relations. At Oncode - together with her colleagues - Elize produces the monthly newsletters for Oncode Investigators & Researchers and the Oncode digital magazine. She publishes content for the Oncode website and is responsible for all social media channels. She enjoys discussing science with researchers and support them in their outreach.
Jeroen de Ridder
Cell-free DNA biomarkers can help to identify treatment responders and non-responders of head and neck cancer patients
The team of Jeroen de Ridder finalized a Clinical Proof of Concept (CPoC) study in which they tested the feasibility of circulating tumor DNA (ctDNA) analysis in head- and neck cancer patients as treatment response identifier. Their results are promising and more extensive validation in larger patient cohorts is underway.
Bianca-OliviaNita

<span>Bianca-Olivia</span><span>Nita</span>